Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 62,300 shares, a growth of 65.7% from the December 15th total of 37,600 shares. Based on an average daily trading volume, of 55,200 shares, the days-to-cover ratio is currently 1.1 days.

Insider Buying and Selling at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 27,502 shares of the stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $10.98 per share, with a total value of $301,971.96. Following the purchase, the director now directly owns 7,981,725 shares in the company, valued at $87,639,340.50. The trade was a 0.35 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Benitec Biopharma

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,102 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after buying an additional 20,012 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma during the 3rd quarter worth about $274,000. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma in the 2nd quarter valued at about $358,000. Finally, Nantahala Capital Management LLC bought a new position in Benitec Biopharma in the 2nd quarter valued at about $5,881,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Trading Up 3.9 %

NASDAQ:BNTC traded up $0.40 on Wednesday, hitting $10.78. The company’s stock had a trading volume of 75,459 shares, compared to its average volume of 48,307. Benitec Biopharma has a one year low of $2.69 and a one year high of $13.29. The firm has a market capitalization of $250.27 million, a P/E ratio of -3.80 and a beta of 0.82. The stock has a fifty day moving average of $11.09 and a two-hundred day moving average of $9.98.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BNTC. JMP Securities increased their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a report on Monday, October 14th. HC Wainwright started coverage on shares of Benitec Biopharma in a report on Monday, December 16th. They issued a “buy” rating and a $28.00 price target for the company. Baird R W raised Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th. Oppenheimer initiated coverage on Benitec Biopharma in a report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Benitec Biopharma currently has an average rating of “Buy” and a consensus target price of $24.43.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.